Oil Prices Slip Slightly as Markets Weigh Geopolitical Risks and Supply Glut Concerns 
Asian Currencies Trade Flat as Dollar Weakens in Thin New Year Trading 
U.S. Dollar Starts 2026 Weak as Yen, Euro and Sterling Hold Firm Amid Rate Cut Expectations 
South Korea Exports Hit Record High as Global Trade Momentum Builds 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Gold Prices Rebound in Europe as Geopolitical Tensions and Fed Outlook Support Bullion 
South Korea Factory Activity Returns to Growth in December on Export Rebound 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Trump Delays Tariff Increases on Furniture and Cabinets for One More Year 
Forex Markets Hold Steady as Traders Await Fed Minutes Amid Thin Year-End Volumes 
U.S. Stock Index Futures Steady as Markets Await Fed Policy Clues in Holiday-Thinned Trade 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
